Online citations, reference lists, and bibliographies.
← Back to Search

Permeability Issues In Nasal Drug Delivery.

P. Arora, S. Sharma, S. Garg
Published 2002 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The nasal route is one of the most permeable and highly vascularized site for drug administration ensuring rapid absorption and onset of therapeutic action. It has been potentially explored as an alternative route for drugs with poor bioavailability and for the delivery of biosensitive and high molecular weight (MW) compounds such as proteins, peptides, steroids, vaccines, and so on. This review discusses the major factors affecting the permeability of drugs or biomolecules through the nasal mucosa, including biological, formulation and device-related factors. This information could potentially help to achieve desired plasma concentrations of drugs without compromising or altering the normal physiology of the nasal cavity.
This paper references
10.1111/j.1469-7793.1997.823ba.x
Sympathetic and parasympathetic interaction in vascular and secretory control of the nasal mucosa in anaesthetized dogs
M. Revington (1997)
The influence of glycoprotein hormones selected properties of selected properties of glycoprotein hormones on their absorption after intranasal administration in foxes.
F. Ryszka (2000)
10.1210/JCEM.76.4.8473411
Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study.
L. Hedin (1993)
Nasal mucus secretion.
Z. Marom (1984)
10.1016/S0168-3659(01)00454-0
Absorption of water-soluble compounds with different molecular weights and.
A. Yamamoto (2001)
10.1146/ANNUREV.PA.33.040193.002123
Respiratory tract uptake of inhalants and metabolism of xenobiotics.
A. Dahl (1993)
10.1016/0168-3659(94)00114-A
Proliposomes as an intranasal dosage form for the sustained delivery of propranolol
Byung-Nak Ahn (1995)
10.3109/10611869909085518
Improved nasal bioavailability of FITC-dextran (Mw 4300) from mucoadhesive microspheres in rabbits.
M. A. El-shafy (2000)
10.1016/S0169-409X(97)00067-7
Nasal delivery systems and their effect on deposition and absorption.
Vidgren (1998)
Distribution of mucus producing elements in the respiratory tract. Differences between upper and lower airway.
M. Tos (1983)
10.1023/A:1015884026056
Nasal Absorption Enhancers for Biosynthetic Human Growth Hormone in Rats
D. O'hagan (2004)
10.1258/0022215011908694
Most patients overdose on topical nasal corticosteroid drops: an accurate delivery device is required.
R. Patel (2001)
10.1016/S0168-3659(97)00204-6
The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins.
A. Bernkop-Schnürch (1998)
10.1023/A:1015952320372
Drug Absorption Through Mucosal Membranes: Effect of Mucosal Route and Penetrant Hydrophilicity
D. C. Corbo (2004)
10.1254/JJP.48.15
A new rhinitis model using chemical mediators in rats.
M. Misawa (1988)
10.1097/00005537-200104000-00008
Classification of Cilio‐Inhibiting Effects of Nasal Drugs
P. Merkus (2001)
10.1002/JPS.2600760905
Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats. II: Histological aspects of the nasal mucosa in relation to the absorption variation due to the effects of pH and osmolarity.
T. Ohwaki (1987)
10.1016/0091-6749(94)90122-8
The human nasal response to capsaicin.
G. Philip (1994)
10.1002/JPS.2600790304
Characterization of the barrier properties of mucosal membranes.
D. C. Corbo (1990)
10.1038/sj.gt.3301565
Steroid hormone enhancement of gene delivery to a human airway epithelial cell line in vitro and mouse airways in vivo
J. Wiseman (2001)
10.1023/A:1018911206646
Drug Metabolism in the Nasal Mucosa
Mohamadi A. Sarkar (2004)
10.1016/S0378-5173(01)00873-0
In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits.
S. T. Lim (2002)
10.1046/j.1464-410x.2001.00068.x
An assessment of the clinical efficacy of intranasal desmopressin spray in the treatment of renal colic
T. Lopes (2001)
10.1016/S0169-409X(97)00058-6
Anatomy, physiology and function of the nasal cavities in health and disease.
Dahl (1998)
10.1002/JBM.1227
In situ gelling and mucoadhesive polymer vehicles for controlled intranasal delivery of plasmid DNA.
Jeong-Sook Park (2002)
10.1016/S0169-409X(01)00166-1
Intranasal vaccination against plague, tetanus and diphtheria.
H. O. Alpar (2001)
10.1016/0378-5173(81)90058-2
Absorption of drugs from the nasal mucosa of rat
Hirai Shinichiro (1981)
10.1111/j.2042-7158.1992.tb05462.x
Di‐iodo‐l‐tyrosine‐labelled Dextrans as Molecular Size Markers of Nasal Absorption in the Rat
A. Fisher (1992)
10.1016/S0378-5173(01)00736-0
Improved nasal bioavailability of elcatonin by insoluble powder formulation.
F. Ishikawa (2001)
10.1016/S0142-9612(00)00011-9
Transmucosal delivery systems for calcitonin: a review.
M. Torres-Lugo (2000)
10.2165/00002018-200023010-00002
Safety of Inhaled and Intranasal Corticosteroids
B. Lipworth (2000)
10.1159/000028017
Delivery Systems and Adjuvants for Vaccination against HIV
D. Velin (1998)
10.3109/02652049809006849
Emulsion formulations of testosterone for nasal administration.
K. Ko (1998)
10.1002/JPS.2600740605
Mechanism of nasal absorption of drugs I: Physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats.
C. Huang (1985)
10.1248/CPB.37.3359
Effect of dose, pH, and osmolarity on nasal absorption of secretin in rats. III. In vitro membrane permeation test and determination of apparent partition coefficient of secretion.
T. Ohwaki (1989)
10.3109/00016488809106437
[Circadian changes in the secretory activity of the nasal mucosa].
D. Passali (1987)
10.1016/0169-409X(93)90015-V
The relevance of nasal physiology to the design of drug absorption studies
S. Gizurarson (1993)
10.1016/S0378-5173(00)00506-8
Lipid emulsions as vehicles for enhanced nasal delivery of insulin.
R. Mitra (2000)
10.1248/BPB.17.1375
Effects of surfactants and protease inhibitors on nasal absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats.
M. Machida (1994)
10.1111/j.2042-7158.1997.tb06769.x
Absorption of Ciprofloxacin and Norfloxacin when Administered as Niosome‐encapsulated Inclusion Complexes
S. A. D'Souza (1997)
10.1111/J.1471-0528.1987.TB02258.X
Nasal absorption of progesterone in women
M. Dalton (1987)
10.1016/S0169-409X(98)00073-8
Intranasal insulin delivery and therapy.
Hinchcliffe (1999)
10.1016/S0169-409X(97)00066-5
Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption.
Huang (1998)
10.1016/S0169-409X(97)00059-8
Nasal mucociliary clearance as a factor in nasal drug delivery.
Merkus (1998)
10.1023/A:1007583422634
Enhancement of the Systemic and CNS Specific Delivery of L-Dopa by the Nasal Administration of Its Water Soluble Prodrugs
H. Kao (2004)
10.1002/JPS.2600740511
Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats.
T. Ohwaki (1985)
10.1111/j.2042-7158.1996.tb03919.x
Transport and Metabolic Pathway of Thymocartin (TP4) in Excised Bovine Nasal Mucosa
S. Lang (1996)
10.1248/CPB.43.2232
Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in hydroxypropyl-beta-cyclodextrin.
K. Abe (1995)
10.1002/BIT.1095
Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis.
Y. Yuki (2001)
10.3109/00016487609120888
Diurnal variation of nasal protein concentration.
N. Mygind (1976)
10.1016/S0169-409X(01)00175-2
Synthetic biomimetic supra molecular Biovector (SMBV) particles for nasal vaccine delivery.
P. Hoegen (2001)
[The transnasal route of drug administration. Aspects of nasal anatomy and physiology].
P. Wüthrich (1989)
10.1002/JPS.2600760709
Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity.
C. Mcmartin (1987)
10.1002/JPS.2600691215
Nasal absorption of propranolol from different dosage forms by rats and dogs.
A. Hussain (1980)
Direct drug transport from the nasal cavity to the cerebrospinal fluid. A new strategy for drug delivery to the brain
T. Sakane (1997)
10.1211/0022357011775145
The biopharmaceutical aspects of nasal mucoadhesive drug delivery
M. I. Ugwoke (2001)
[The effect of nasal sensory nerve on the enhanced nasal blood vessel permeability caused by histamine].
P. Yang (1991)
10.1016/S0022-510X(01)00532-9
Intranasal administration of insulin-like growth factor-I bypasses the blood–brain barrier and protects against focal cerebral ischemic damage
X. Liu (2001)
10.1023/A:1015830907632
The Nasal Mucociliary Clearance: Relevance to Nasal Drug Delivery
N. G. Schipper (2004)
10.1021/BI981219H
Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane.
M. Schmidt (1998)
10.1016/S0168-3659(00)00330-8
A novel bioadhesive intranasal delivery system for inactivated influenza vaccines.
M. Singh (2001)
Nasal systemic drug delivery
Y. Chien (1989)
10.1023/A:1015949013644
The Use of α-Aminoboronic Acid Derivatives to Stabilize Peptide Drugs During Their Intranasal Absorption
M. Hussain (2004)
10.1016/S0169-409X(01)00115-6
Drug transfer through mucus.
K. Khanvilkar (2001)
Systemic delivery of peptides and proteins across absorptive mucosae.
Sayani Ap (1996)
10.1023/A:1015891727080
Model of Disposition of Drugs Administered into the Human Nasal Cavity
I. Gonda (2004)
10.1002/JPS.10083
Testosterone 17beta-N,N-dimethylglycinate hydrochloride: A prodrug with a potential for nasal delivery of testosterone.
A. Hussain (2002)
[Studies on octanol-water partition coefficient and nasal drug absorption].
X. Jiang (1997)
10.1002/JPS.2600751113
Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin.
A. Harris (1986)
10.1081/DDC-100102275
The relationship between the rigidity of the liposomal membrane and the absorption of insulin after nasal administration of liposomes modified with an enhancer containing insulin in rabbits.
K. Muramatsu (1999)
10.1248/CPB.39.2456
The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug.
T. Sakane (1991)
10.1016/S0169-409X(97)00063-X
Effects of physicochemical properties and other factors on systemic nasal drug delivery.
Roméo (1998)
10.1016/S0169-409X(97)00065-3
Prodrugs for nasal drug delivery.
Mitra (1998)
Nasal mucosa as an absorption barrier
A. Cornaz (1994)
10.1023/A:1015947509295
The Adjuvant Effect of Bacitracin on Nasal Absorption of Gonadorelin and Buserelin in Rats
Susanne Raehs (2004)
10.1016/0169-409X(93)90014-U
Mucociliary clearance and drug delivery via the respiratory tract
A. Lansley (1993)
10.1111/j.2042-7158.1994.tb03746.x
Factors Influencing Gel‐strengthening at the Mucoadhesive‐mucus Interface
S. A. Mortazavi (1994)
10.1016/0091-6749(84)90403-2
Human respiratory mucus.
M. Kaliner (1986)



This paper is referenced by
10.1080/21691401.2017.1420073
Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting
Kousalya Selvaraj (2018)
10.1016/j.brainresbull.2018.10.009
Evaluation of intranasal delivery route of drug administration for brain targeting
F. Erdő (2018)
10.1016/j.jneumeth.2015.11.027
Rapid intranasal delivery of chloramphenicol acetyltransferase in the active form to different brain regions as a model for enzyme therapy in the CNS
Abhilash P. Appu (2016)
A review on factors affecting the design of nasal drug delivery system
R. C. Dhakar (2011)
10.1016/B978-0-12-384964-9.00010-4
Oral Delivery of Proteins and Peptides: Concepts and Applications
Gaurang Patel (2011)
REVIEW ON NASAL DRUG DELIVERY SYSTEM WITH RECENT ADVANCEMNT
P. Sharma (2011)
10.1016/J.EJPB.2006.05.017
Nasal absorption of metoclopramide from different Carbopol 981 based formulations: In vitro, ex vivo and in vivo evaluation.
C. Taş (2006)
10.21608/AJPS.2012.7154
IMPROVEMENT OF THE BIOAVAILABILITY OF BUSPIRONE HCL USING INTRANASAL DELIVERY SYSTEMS
Hamza Bshara (2012)
10.1002/PSC.701
Small peptides, big world: biotechnological potential in neglected bioactive peptides from arthropod venoms
A. M. Pimenta (2005)
10.1155/2014/378048
Emerging Trends in Noninvasive Insulin Delivery
A. Verma (2014)
A REVIEW OF RECENT TRENDS IN NON-INVASIVE INSULIN THERAPY FOR DIABETES MELLITUS
S. Bala (2014)
1 Opportunities and Challenges for the Nasal Administration of Nanoemulsions 1
C. Comfort (2014)
10.1002/ccr3.3
Reversal of experimental paralysis in a human by intranasal neostigmine aerosol suggests a novel approach to the early treatment of neurotoxic envenomation
M. Lewin (2013)
10.1016/J.EJPB.2007.08.013
Evaluation of brain-targeting for the nasal delivery of ergoloid mesylate by the microdialysis method in rats.
J. Chen (2008)
PROLIPOSOMES: A BRIEF OVERVIEW OF NOVEL DELIVERY SYSTEM
Jessy Shaji and Vinay Bhatia (2013)
NASAL DRUG DELIVERY SYSTEM AN OVERVIEW
Pawar Piyush Nandkumar (2015)
10.1080/10717544.2018.1464081
Modification of translationally controlled tumor protein-derived protein transduction domain for improved intranasal delivery of insulin
Hae-duck Bae (2018)
10.1016/j.neuropharm.2018.06.006
Intranasal administration of progesterone: A potential efficient route of delivery for cerebroprotection after acute brain injuries
R. Guennoun (2019)
10.1007/s13318-011-0059-4
In vitro–in situ permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfate
E. Gundogdu (2011)
10.4333/KPS.2004.34.6.483
In vitro Transport of Fexofenadine.HCl in Deformable Liposomes Across the Human Nasal Epithelial Cell Monolayers
H. Lin (2004)
10.1101/2020.09.17.302703
Development of an MRI Compatible Nasal Drug Delivery Method: Probing Nicotine Addiction Dynamics
L. Mujica-Parodi (2020)
10.1201/B18211-4
Respiratory and Olfactory Routes
E. Igarashi (2015)
10.3390/APP9112219
Chitosan-Based Nanocarriers for Nose to Brain Delivery
B. Aderibigbe (2019)
10.3109/03639045.2013.842578
Development of thiolated poly(acrylic acid) microparticles for the nasal administration of exenatide
G. Millotti (2014)
10.1038/nrd.2018.183
Non-invasive delivery strategies for biologics
Aaron C. Anselmo (2019)
10.1211/0022357023646
Transport of deslorelin, an LHRH agonist, is vectorial and exhibits regional variation in excised bovine nasal tissue
K. Koushik (2004)
10.1101/042416
Preprint: A robust peptidomics mass spectrometry platform for measuring oxytocin in plasma and serum
Ole Kristian Brandtzaeg (2016)
10.5152/TJAR.2019.45087
Comparison of Intranasal Dexmedetomidine Versus Intranasal Ketamine as Premedication for Level of Sedation in Children Undergoing Radiation Therapy: A Prospective, Randomised, Double-Blind Study
Praneeth Suvvari (2020)
10.1016/j.ijpharm.2020.119725
AmyloLipid Nanovesicles: A Self-Assembled Lipid-Modified Starch Hybrid System Constructed for Direct Nose-to-Brain Delivery of Curcumin.
A. Sintov (2020)
Synthesis, characterization and cytotoxicity evaluation of carboxylated carbon nanotubes functionalized with silibinin, betulinic acid and levodopa for drug delivery
J. Tan (2015)
10.1016/j.sjbs.2019.11.008
Poloxamer-chitosan-based Naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia
N. Ahmad (2020)
Intranasal drug delivery system- A glimpse to become maestro
S. Upadhyay (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar